menu search

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast cell activation pathways, including KIT-mediated activation– SAN CARLOS, Calif., June 12, 2023 (GLOBE NEWSWIRE) — Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector […] The post Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highl... Read More
Posted: Jun 12 2023, 11:02
Author Name: forextv
Views: 081239

Search within

Pages Search Results: